Prognostic value of Laurén classification and c-erbB-2 oncogene overexpression in adenocarcinoma of the esophagus and gastroesophageal junction.
about
Advanced gastric cancer: Current treatment landscape and future perspectivesMolecular classification and prediction in gastric cancerNOTCH receptors in gastric and other gastrointestinal cancers: oncogenes or tumor suppressors?Systematic review and meta-analysis of immunohistochemical prognostic biomarkers in resected oesophageal adenocarcinomaMolecular biology of Barrett's adenocarcinoma.Double contrast-enhanced ultrasonography evaluation of preoperative Lauren classification of advanced gastric carcinoma.Alterations in Barrett's-related adenocarcinomas: a proteomic approach.Relationship between HER-2 overexpression and brain metastasis in esophageal cancer patients.Molecular targeting to treat gastric cancer.Functional polymorphisms associated with disease-free survival in resected carcinoma of the esophagus.Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab.Gastric cancer: Classification, histology and application of molecular pathology.The role of receptor tyrosine kinase inhibition in treating gastrointestinal malignancy.Squamous Cell Carcinoma - Similarities and Differences among Anatomical Sites.A concordant expression pattern of fatty acid synthase and membranous human epidermal growth factor receptor 2 exists in gastric cancer and is associated with a poor prognosis in gastric adenocarcinoma patients.Relative Prognostic Value of Human Epidermal Growth Factor Receptor 2 (HER2) Expression in Operable Oesophagogastric Cancer.Targeted therapy in gastroesophageal cancers: past, present and future.Clinicopathological characteristics of human epidermal growth factor receptor 2-positive Barrett's adenocarcinoma.Expression levels of HER2 and MRP1 are not prognostic factors of long-term survival in 829 patients with esophageal squamous cell carcinomaHER-2 Expression in Brain Metastases from Colorectal Cancer and Corresponding Primary Tumors: A Case Cohort Series.Clinicopathological factors associated with HER2 status in gastric cancer: results from a prospective multicenter observational cohort study in a Japanese population (JFMC44-1101).Personalizing therapies for gastric cancer: molecular mechanisms and novel targeted therapiesAnalysis of risk factors for the interval time, number and pattern of hepatic metastases from gastric cancer after radical gastrectomy.Esophageal cancer: current and emerging therapy modalities.Epidemiology of gastric cancer in the gangetic areas of west bengal.Chromosomal abnormalities and novel disease-related regions in progression from Barrett's esophagus to esophageal adenocarcinoma.HER2 status in Barrett's esophagus & esophageal cancer: a meta analysis.Role of human epidermal growth factor receptor 2 in gastric cancer: biological and pharmacological aspects.Her-2/neu testing and therapy in gastroesophageal adenocarcinoma.Systematic review and meta-analysis of the influence of HER2 expression and amplification in operable oesophageal cancer.Molecular targeted therapies in advanced gastric cancer: does tumor histology matter?Advances in biomarkers for esophageal cancer.Lauren subtypes of advanced gastric cancer influence survival and response to chemotherapy: real-world data from the AGAMENON National Cancer Registry.Oxidative Phosphorylation System in Gastric Carcinomas and Gastritis.Is there an association between invasive lobular carcinoma of the breast and a family history of gastric cancer?c-erb B-2 expression is associated with tumor location and venous invasion and influences survival of patients with gastric carcinoma.lncRNA BG981369 Inhibits Cell Proliferation, Migration, and Invasion, and Promotes Cell Apoptosis by SRY-Related High-Mobility Group Box 4 (SOX4) Signaling Pathway in Human Gastric Cancer.Human epidermal growth factor receptor 2 overexpression and amplification in endoscopic biopsies and resection specimens in esophageal and junctional adenocarcinoma.Genome-wide analysis of esophageal adenocarcinoma yields specific copy number aberrations that correlate with prognosis.Feasibility of differentiating T3 from T4a gastric cancer in different Lauren classification by determining serosa invasion: Diagnostic performance of high enhanced serosa sign.
P2860
Q26764934-4641D3F9-AB71-4E35-8469-4ADE7DD0141EQ26783806-BE2EA52C-C863-4459-BD9F-25E77FB30E39Q28074478-E0280BC0-4E44-4BDF-B305-DDB04D0DBDB8Q28085367-25AE4A70-A292-4ED6-A530-8AB852CC0B47Q30327935-A93755E3-657B-436C-80DA-FC33879C05FDQ30471156-7C1F4FA1-1CB9-4DB0-89EE-9DF720B04F17Q33305454-7F1C460E-3E17-45AA-96DC-A202454F51CDQ34285753-79B2796E-A41C-4113-82DA-53B11760E8A7Q34326593-E923A7FF-B8AE-4D51-9387-3464620D1F61Q34500998-30494E8F-275C-4C51-8ABD-7427B989EB3DQ34554455-BBDF0525-1603-43DF-BF8B-17FD76B01C47Q34642023-F351E7EC-B8D2-4757-88E4-684ACC1661BDQ35094666-7C7554CD-0F60-46AD-9715-B7E86BE302F5Q35220347-525E5CCF-2730-4A4B-A638-48CA053222EDQ36085663-B521CAAD-EB8C-46DF-86F8-0B41CDEB8313Q36140927-0AA1DA21-F979-4EA7-955F-E8B2345CB5C2Q36294579-4F9C061D-2B42-4373-85AC-D8E827C797AAQ36410392-548E7C4E-A987-409C-AA3A-76878DA2FE02Q36503276-65A4A737-F81E-4BC6-BD56-92F12C5A44C7Q36655951-177286BF-5480-4B21-B472-FC6F5204237EQ36999892-94971B1D-5473-4A17-9CDA-2EAF77DD5675Q37241496-6D683C6F-6A2B-4ACD-A244-70B10314CB0CQ37248789-030A0460-970D-43E5-9942-6A8E24C941A9Q37256825-7FC252B1-8ADC-44A3-943D-FB0FBF629025Q37286328-D4CE6D67-D285-4386-A2EE-B82A099B672DQ37398079-56690C66-F74E-41C6-AF0B-417D5C044DDEQ37522215-93D7B6B7-0E08-4697-8269-D8D81D379E85Q37724647-6839F534-0FD7-4823-B188-71A171601F1EQ37824265-ADA9E9DE-DF0B-4E3A-8EBF-CD02C1E1DFBCQ38030442-7474D573-B14B-41A9-9D9F-3AB328EAFFAFQ38074157-46E8E477-C617-4DC9-8BDD-C1BF619722F2Q38153443-EE98E4D8-D466-4834-AEC5-B3E286BAFA7BQ38647893-E64212C5-92B2-4989-8BCD-96ED5002A6A6Q40119667-8AD1AFAB-BD9A-4A45-8DBB-433367AFB6D1Q41377330-9FEDF03B-21B3-47A8-B860-559542EE59CEQ44255226-0DD2485D-0988-4576-BACB-1D1E3C93FA43Q49339227-9DFB6A54-16CF-43EF-8A47-49E428F2AF41Q51103473-C0E93D02-8157-4E68-B176-A64FF2061611Q51121654-66C70344-FEC0-4384-B05C-4E0CB392FE46Q54967237-E74A24C3-EF70-4855-88EF-86F6C0660071
P2860
Prognostic value of Laurén classification and c-erbB-2 oncogene overexpression in adenocarcinoma of the esophagus and gastroesophageal junction.
description
1999 nî lūn-bûn
@nan
1999 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Prognostic value of Laurén cla ...... and gastroesophageal junction.
@ast
Prognostic value of Laurén cla ...... and gastroesophageal junction.
@en
Prognostic value of Laurén cla ...... and gastroesophageal junction.
@nl
type
label
Prognostic value of Laurén cla ...... and gastroesophageal junction.
@ast
Prognostic value of Laurén cla ...... and gastroesophageal junction.
@en
Prognostic value of Laurén cla ...... and gastroesophageal junction.
@nl
prefLabel
Prognostic value of Laurén cla ...... and gastroesophageal junction.
@ast
Prognostic value of Laurén cla ...... and gastroesophageal junction.
@en
Prognostic value of Laurén cla ...... and gastroesophageal junction.
@nl
P2093
P1476
Prognostic value of Laurén cla ...... and gastroesophageal junction.
@en
P2093
Offerhaus GJ
Polkowski W
ten Kate FJ
van Lanschot JJ
van Sandick JW
P2888
P304
P356
10.1007/S10434-999-0290-2
P577
1999-04-01T00:00:00Z